ACV meeting statement, Meeting 35, 3 August 2022

Section A: Submissions for registration

The committee provided advice on two submissions:

• Extension of indication for Gardasil 9 by provisional registration (product name Human papillomavirus 9-valent vaccine, recombinant; sponsor Merck Sharp & Dohme (Australia) Pty Ltd).
• New vaccine for pre-exposure and post-exposure prophylaxis against rabies (product name Rabies virus vaccine inactivated; brandname Verorab; sponsor Sanofi).

Details of the ACV advice associated with these premarket items has been or will be released within the Australian Public Assessment Report (AusPAR). To browse all AusPARs see AusPAR search.

Section B: Safety

The committee was not asked to provide advice on any safety matter.

Further information

For further information on the ACV, please visit Advisory Committee on Vaccines  or contact the ACV by email ACV@health.gov.au.